PH27002A - New use of 5HT antagonists - Google Patents
New use of 5HT antagonists Download PDFInfo
- Publication number
- PH27002A PH27002A PH37205A PH37205A PH27002A PH 27002 A PH27002 A PH 27002A PH 37205 A PH37205 A PH 37205A PH 37205 A PH37205 A PH 37205A PH 27002 A PH27002 A PH 27002A
- Authority
- PH
- Philippines
- Prior art keywords
- formula
- alkyl
- hydrogen
- dependency
- methyl
- Prior art date
Links
- 239000003420 antiserotonin agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 37
- 239000005557 antagonist Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 10
- 229960002715 nicotine Drugs 0.000 claims description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 230000003405 preventing effect Effects 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 150000003839 salts Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- -1 hydroxy, amino Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940127240 opiate Drugs 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 28
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 28
- 229960003638 dopamine Drugs 0.000 description 14
- 229960005181 morphine Drugs 0.000 description 14
- 241000700159 Rattus Species 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000001009 nucleus accumben Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- UMQPWGSSJHTJBH-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)-9h-carbazole Chemical compound C1=CNC(C=2C=3NC4=CC=CC=C4C=3C=CC=2)=N1 UMQPWGSSJHTJBH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XJRIDJAGAYGJCK-UHFFFAOYSA-N (1-acetyl-5-bromoindol-3-yl) acetate Chemical compound C1=C(Br)C=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 XJRIDJAGAYGJCK-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 102100031460 Advillin Human genes 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000954177 Bangana ariza Species 0.000 description 1
- 101150071100 CBY2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 238000005773 Enders reaction Methods 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001165465 Farula Species 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101000729999 Homo sapiens Advillin Proteins 0.000 description 1
- UXPNMQCEVMBCIR-UHFFFAOYSA-N Homoaerothionin Natural products C1=C(Br)C(OC)=C(Br)C(O)C11ON=C(C(=O)NCCCCCNC(=O)C=2CC3(ON=2)C(C(Br)=C(OC)C(Br)=C3)O)C1 UXPNMQCEVMBCIR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282858 Hyracoidea Species 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 241000405961 Scomberomorus regalis Species 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QIQSPBXYROQUID-UHFFFAOYSA-N butanedioic acid;2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine;5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid;hydrochloride Chemical compound Cl.OS(O)(=O)=O.OC(=O)CCC(O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 QIQSPBXYROQUID-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3722959 | 1987-07-11 | ||
| DE3735719 | 1987-10-22 | ||
| CH451087 | 1987-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27002A true PH27002A (en) | 1993-02-01 |
Family
ID=27174878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH37205A PH27002A (en) | 1987-07-11 | 1988-07-11 | New use of 5HT antagonists |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5039680A (da) |
| EP (1) | EP0302008A3 (da) |
| JP (1) | JPS6431729A (da) |
| KR (1) | KR890001537A (da) |
| AT (1) | AT401615B (da) |
| AU (3) | AU618008B2 (da) |
| BE (1) | BE1004835A5 (da) |
| DE (1) | DE3822792C2 (da) |
| DK (1) | DK385388A (da) |
| FR (1) | FR2617713A1 (da) |
| GB (2) | GB2206788B (da) |
| HU (1) | HU206042B (da) |
| IT (1) | IT1226632B (da) |
| MY (1) | MY103536A (da) |
| NL (1) | NL8801733A (da) |
| PH (1) | PH27002A (da) |
| PT (1) | PT87958B (da) |
| SE (1) | SE8802570L (da) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| US5198447A (en) * | 1986-11-21 | 1993-03-30 | Glaxo Group Limited | Medicaments |
| JP2765845B2 (ja) * | 1986-11-21 | 1998-06-18 | グラクソ、グループ、リミテッド | 中止症候群の予防の治療薬 |
| DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5166341A (en) * | 1988-07-29 | 1992-11-24 | Dainippon Pharmaceutical Co., Ltd. | 6-amino-1,4-hexahydro-1H-diazepine derivatives |
| US5017573A (en) * | 1988-07-29 | 1991-05-21 | Dainippon Pharmaceutical Co., Ltd. | Indazole-3-carboxylic acid derivatives |
| GB8820650D0 (en) * | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
| US4999382A (en) * | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
| US5276050A (en) * | 1989-08-01 | 1994-01-04 | Glaxo Group Limited | Medicaments |
| EP1022025A3 (en) * | 1991-06-26 | 2002-06-05 | Sepracor, Inc. | Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron |
| JPH05310732A (ja) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US6109269A (en) * | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
| US6218421B1 (en) * | 1999-07-01 | 2001-04-17 | Smithkline Beecham P.L.C. | Method of promoting smoking cessation |
| US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| JP2004506735A (ja) | 2000-08-18 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用キヌクリジン置換アリール化合物 |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282873A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| EP1419161A1 (en) | 2001-08-24 | 2004-05-19 | PHARMACIA & UPJOHN COMPANY | Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| CA2455773A1 (en) * | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
| EP1425286B1 (en) * | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| NZ531786A (en) | 2001-10-02 | 2006-10-27 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| JP2005511613A (ja) * | 2001-11-08 | 2005-04-28 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 疾患治療用アザビシクロ置換ヘテロアリール化合物 |
| BR0214016A (pt) | 2001-11-09 | 2004-10-13 | Upjohn Co | Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr |
| WO2003066595A2 (en) | 2002-02-01 | 2003-08-14 | Euro-Celtique S.A. | 2 - piperazine - pyridines useful for treating pain |
| US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| AU2003217275A1 (en) * | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclic compounds for the treatment of disease |
| JP2005523288A (ja) * | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| BR0307874A (pt) * | 2002-02-20 | 2004-12-28 | Upjohn Co | Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7 |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| US6864261B2 (en) * | 2002-05-02 | 2005-03-08 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7279493B2 (en) * | 2002-06-28 | 2007-10-09 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7262194B2 (en) * | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
| WO2004013137A1 (en) * | 2002-08-01 | 2004-02-12 | Pharmacia & Upjohn Company Llc | 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| US7157462B2 (en) * | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| WO2004039815A2 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases |
| US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| AR044688A1 (es) * | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| PT1641775E (pt) * | 2003-07-03 | 2009-04-23 | Euro Celtique Sa | Derivados de 2-piridina-alcino úteis para o tratamento da dor |
| PL1867644T3 (pl) | 2003-07-24 | 2009-10-30 | Euro Celtique Sa | Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu |
| NZ545506A (en) | 2003-07-24 | 2009-11-27 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| SI1867644T1 (sl) * | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| CN1832935A (zh) * | 2003-08-01 | 2006-09-13 | 欧洲凯尔特公司 | 用于治疗疼痛的治疗药 |
| SI1664041T1 (sl) * | 2003-09-22 | 2008-12-31 | Euro Celtique Sa | Fenil-karboksamidne spojine, uporabne za tretiranje bolečine |
| CA2537004A1 (en) * | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| KR100867188B1 (ko) * | 2003-12-30 | 2008-11-06 | 유로-셀띠끄 소시에떼 아노님 | 통증 치료에 유용한 피페라진 |
| US20070043100A1 (en) * | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| US20060100263A1 (en) * | 2004-11-05 | 2006-05-11 | Anthony Basile | Antipyretic compositions and methods |
| RU2008107336A (ru) * | 2005-07-27 | 2009-09-10 | Дов Фармасьютикал, Инк. (Us) | Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| US8138377B2 (en) * | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| EP2091936B1 (en) * | 2007-04-27 | 2013-05-15 | Purdue Pharma LP | Therapeutic agents useful for treating pain |
| WO2008153937A2 (en) * | 2007-06-06 | 2008-12-18 | Dov Pharmaceutical, Inc. | Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
| US9062042B2 (en) * | 2010-01-11 | 2015-06-23 | Astraea Therapeutics, Llc | Nicotinic acetylcholine receptor modulators |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| RS62301B1 (sr) | 2013-12-20 | 2021-09-30 | Astex Therapeutics Ltd | Biciklična heterociklična jedinjenja i njihove upotrebe u terapiji |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59004A0 (en) * | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| BE897117A (fr) * | 1982-06-29 | 1983-12-23 | Sandoz Sa | Nouveaux derives de la piperidine leur preparation et leur utilisation comme medicaments |
| FI74707C (fi) * | 1982-06-29 | 1988-03-10 | Sandoz Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror. |
| DE3429830A1 (de) * | 1983-08-26 | 1985-03-07 | Sandoz-Patent-GmbH, 7850 Lörrach | Automatische carbonsaeure- und sulfonsaeureester oder -amide |
| DE3445377A1 (de) * | 1983-12-23 | 1985-07-04 | Sandoz-Patent-GmbH, 7850 Lörrach | Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen |
| KR920003064B1 (ko) * | 1984-01-25 | 1992-04-13 | 글락소 그룹 리미티드 | 헤테로시클릭 화합물의 제조방법 |
| EP0201165B1 (en) * | 1985-03-14 | 1994-07-20 | Beecham Group Plc | Medicaments for the treatment of emesis |
| EP0498466B1 (en) * | 1985-04-27 | 2002-07-24 | F. Hoffmann-La Roche Ag | Indazole-3-carboxamide and -3-carboxylic acid derivatives |
| GR861128B (en) * | 1985-05-06 | 1986-08-26 | Sandoz Ag | New use of dopamine agonists |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8520616D0 (en) * | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
| GB8701494D0 (en) * | 1987-01-23 | 1987-02-25 | Glaxo Group Ltd | Chemical compounds |
| JP2765845B2 (ja) * | 1986-11-21 | 1998-06-18 | グラクソ、グループ、リミテッド | 中止症候群の予防の治療薬 |
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| GR871809B (en) * | 1986-11-28 | 1988-03-07 | Glaxo Group Ltd | Process for the preparation of tricyclic ketones |
| GB8630080D0 (en) * | 1986-12-17 | 1987-01-28 | Glaxo Group Ltd | Medicaments |
| DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| DE3851597T2 (de) * | 1987-09-03 | 1995-01-26 | Glaxo Group Ltd., London | Lactamderivate. |
| ZA886585B (en) * | 1987-09-08 | 1990-05-30 | Lilly Co Eli | Specific 5-ht,antagonists |
| GB8723157D0 (en) * | 1987-10-02 | 1987-11-04 | Beecham Group Plc | Compounds |
| EP0322016A1 (en) * | 1987-12-10 | 1989-06-28 | Duphar International Research B.V | 1,7-Annelated indolecarboxylic acid esters and -amides |
| JPH0249772A (ja) * | 1988-04-07 | 1990-02-20 | Glaxo Group Ltd | イミダゾール誘導体 |
-
1988
- 1988-07-06 DE DE3822792A patent/DE3822792C2/de not_active Expired - Fee Related
- 1988-07-07 EP EP19880810470 patent/EP0302008A3/en not_active Withdrawn
- 1988-07-08 DK DK385388A patent/DK385388A/da not_active Application Discontinuation
- 1988-07-08 HU HU883610A patent/HU206042B/hu not_active IP Right Cessation
- 1988-07-08 NL NL8801733A patent/NL8801733A/nl not_active Application Discontinuation
- 1988-07-08 FR FR8809350A patent/FR2617713A1/fr active Granted
- 1988-07-08 SE SE8802570A patent/SE8802570L/xx not_active Application Discontinuation
- 1988-07-08 AT AT0177688A patent/AT401615B/de not_active IP Right Cessation
- 1988-07-08 GB GB8816298A patent/GB2206788B/en not_active Expired - Lifetime
- 1988-07-08 MY MYPI88000755A patent/MY103536A/en unknown
- 1988-07-08 PT PT87958A patent/PT87958B/pt not_active IP Right Cessation
- 1988-07-09 KR KR1019880008589A patent/KR890001537A/ko not_active Application Discontinuation
- 1988-07-09 JP JP63171704A patent/JPS6431729A/ja active Pending
- 1988-07-11 BE BE8800802A patent/BE1004835A5/fr not_active IP Right Cessation
- 1988-07-11 AU AU18920/88A patent/AU618008B2/en not_active Ceased
- 1988-07-11 PH PH37205A patent/PH27002A/en unknown
- 1988-07-11 IT IT8848172A patent/IT1226632B/it active
-
1990
- 1990-01-19 US US07/467,598 patent/US5039680A/en not_active Expired - Fee Related
-
1991
- 1991-03-05 GB GB9104598A patent/GB2240475B/en not_active Expired - Lifetime
- 1991-10-07 AU AU85630/91A patent/AU643075B2/en not_active Ceased
- 1991-10-07 AU AU85628/91A patent/AU633762B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HUT50038A (en) | 1989-12-28 |
| AU8562891A (en) | 1991-12-05 |
| AU1892088A (en) | 1989-01-12 |
| EP0302008A3 (en) | 1992-12-23 |
| US5039680A (en) | 1991-08-13 |
| DK385388A (da) | 1989-01-12 |
| GB2240475A (en) | 1991-08-07 |
| GB2206788B (en) | 1992-03-25 |
| FR2617713B1 (da) | 1994-08-19 |
| AU8563091A (en) | 1991-12-12 |
| DE3822792A1 (de) | 1989-01-19 |
| GB2206788A (en) | 1989-01-18 |
| KR890001537A (ko) | 1989-03-27 |
| AT401615B (de) | 1996-10-25 |
| FR2617713A1 (fr) | 1989-01-13 |
| IT1226632B (it) | 1991-01-28 |
| NL8801733A (nl) | 1989-02-01 |
| GB9104598D0 (en) | 1991-04-17 |
| PT87958B (pt) | 1995-03-01 |
| AU643075B2 (en) | 1993-11-04 |
| AU633762B2 (en) | 1993-02-04 |
| JPS6431729A (en) | 1989-02-02 |
| DK385388D0 (da) | 1988-07-08 |
| BE1004835A5 (fr) | 1993-02-09 |
| GB2240475B (en) | 1992-03-18 |
| SE8802570D0 (sv) | 1988-07-08 |
| DE3822792C2 (de) | 1997-11-27 |
| SE8802570L (sv) | 1989-03-28 |
| HU206042B (en) | 1992-08-28 |
| EP0302008A2 (en) | 1989-02-01 |
| MY103536A (en) | 1993-07-31 |
| PT87958A (pt) | 1989-06-30 |
| IT8848172A0 (it) | 1988-07-11 |
| AU618008B2 (en) | 1991-12-12 |
| GB8816298D0 (en) | 1988-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH27002A (en) | New use of 5HT antagonists | |
| US5198459A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| Bountra et al. | Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets | |
| DE69231395T3 (de) | Neue medizinische Indikation für Tachykinin-Antagonisten | |
| JP2765845B2 (ja) | 中止症候群の予防の治療薬 | |
| JP2608079B2 (ja) | 医 薬 | |
| SK281603B6 (sk) | Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie | |
| CZ300513B6 (cs) | Farmaceutický prostredek pro potlacení menopauzálních návalu horka | |
| IL135235A0 (en) | Method and composition for preventing nephrotoxicity caused by cyclosporins and tacrolimus | |
| Carlsson et al. | Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine | |
| US6221878B1 (en) | Method for treatment of depression | |
| US5519044A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| Blackham et al. | The effect of FK506 and cyclosporin A on antigen‐induced arthritis | |
| SA94150003B1 (ar) | تركيبات تحاميل تحتوى على ثنائي هيدرات اونداسيترون | |
| Rao et al. | Ifenprodil and SL 82.0715 antagonize N-methyl-D-aspartate (NMDA)-coupled glycine receptor responses in vivo | |
| US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
| US4522820A (en) | Trans-dihydrolisuride antipsychotic | |
| CA2416706C (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
| GB2240476A (en) | Use of 5HT-3 antagonist for preventing or reducing dependence | |
| DE69625819T2 (de) | Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor | |
| AU642765B2 (en) | Use of N-(1-hexahydroazepinylalkyl)acetamides for the treatment of cholinergic transmission disorders | |
| Eddy | METOPON HYDROCHLORIDE:(Methyldihydromorphinone Hydrochloride) | |
| FUJII et al. | Cross interaction between methamphetamine and scopolamine by means of ambulatory activity in mice | |
| Zein-Eldin et al. | CLINICAL, HAEMATOBIOCHEMICAL AND ELECTROCARDIGRAPHIC CHANGES OF DIARRHEIC SHEEP AND CHANGES FOLLOWING TREATMENT BY NUTMEG AND OXYTETRACYCLINE. | |
| JPH0624978A (ja) | 抗アレルギー剤 |